Last updated: March 13, 2026
What is the Product?
NDC 17478-0715 refers to a prescription drug marketed primarily for specific therapeutic indications. The NDC code corresponds to Tafamidis meglumine, a transthyretin amyloid fibril stabilizer used to treat transthyretin amyloid cardiomyopathy and polyneuropathy. Its primary brand is Vyndaqel / Vyndamax (Purdue Pharma/ Pfizer licensing).
Market Size and Demand Drivers
Indications Covered
- Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A progressive heart condition caused by amyloid deposits.
- Inherited Transthyretin Amyloidosis with Polyneuropathy (ATTR-PN): A rare systemic disease affecting nerves and organs.
Incidence Estimates
- ATTR-CM: Approximately 10,000 to 20,000 diagnosed US patients; likely underdiagnosed.
- ATTR-PN: Around 50,000 globally, with 3,000–5,000 in the US.
Market Penetration
- Limited by diagnostic challenges; early-stage diagnosis remains low.
- Existing awareness campaigns have increased diagnosis over the past 3 years.
Competitive Landscape
- Limited approved alternatives; patisiran (Onpattro) and inotersen (Tegsedi) target ATTR-PN but do not treat cardiomyopathy.
- Other candidates under development face regulatory and pricing hurdles.
Pricing Overview
Current Price Points
| Drug |
Indication |
Wholesale Acquisition Cost (WAC) |
Estimated Net Price (after discounts) |
| Vyndaqel / Vyndamax |
ATTR-CM, ATTR-PN |
$50,000–$100,000 per year |
$35,000–$85,000 per year |
- Price varies based on dosage, formulation, and geographic region.
- Payers and insurers negotiate significant rebates, reducing actual costs.
Pricing Trends (2020-2023)
- Prices remained relatively stable despite increased volume.
- No major price reductions; some payers offer prior authorization or step therapy.
Market Size and Revenue Projections
Current Sales Data
- Estimated US sales in 2022: $900 million.
- Global sales forecast for 2023: $1.2 billion, driven by new market penetrations and expanded reimbursement.
Forecasted Growth
| Year |
Estimated Global Sales |
Growth Rate |
Key Drivers |
| 2023 |
$1.2 billion |
33% |
Increased diagnosis, new country approvals, expanded insurance coverage |
| 2024 |
$1.5 billion |
25% |
Broader clinician education, incremental pricing adjustments |
| 2025 |
$1.8 billion |
20% |
Broader utilization, potential price pressure |
Assumptions
- Stable approval status; no major regulatory setbacks.
- Continued increase in diagnosed patient population.
- Steady reimbursement environment with limited price erosion.
Key Risks and Opportunities
Risks
- Diagnostic delays reducing market penetration.
- Price control proposals, especially in public payers.
- Competition from emerging therapies, including gene silencers or gene editing approaches.
Opportunities
- Expansion into Europe, Asia, and other markets.
- Development of combination therapies.
- Increasing awareness campaigns, improving diagnosis rates.
Regulatory and Policy Landscape
- FDA approval granted in 2019 under accelerated pathways.
- CMS and private payers increasingly recognize ATTR treatments, with coding and coverage supporting reimbursement.
- Ongoing efforts in Europe and Asia; approvals expected in Japan and the EU by 2024.
Summary of Key Data Points
| Aspect |
Details |
| Main indications |
ATTR-CM, ATTR-PN |
| US diagnosed patient base |
10,000–20,000 |
| Global market size |
Approximately $1.2 billion (2023 estimate) |
| Price range |
$50,000–$100,000 annually |
| Current sales (US, 2022) |
~$900 million |
| Growth forecast (2023-2025) |
20–33% annual increase |
Key Takeaways
- The drug exhibits a limited but growing market primarily driven by rare disease diagnosis.
- Pricing remains high but stable; reimbursement policies influence net revenue.
- Market expansion depends on diagnosis rates, regulatory approvals, and competitive developments.
- Forecasts suggest robust growth, contingent on sustained demand and absence of pricing pressures.
FAQs
1. How does the pricing of NDC 17478-0715 compare to similar rare disease treatments?
It is generally higher due to the small patient population, with annual costs between $50,000 and $100,000, comparable to other orphan drugs like Patisiran.
2. What is the likelihood of market expansion into new regions?
There is a significant probability based on the current approval pipeline, especially in Europe and Asia, contingent on regulatory processes.
3. How sensitive is the market to reimbursement policies?
Highly; reimbursement changes, rebate negotiations, and coverage criteria directly impact net revenues.
4. Are there ongoing developments that may threaten current market share?
Yes; new therapies targeting the same indications, including gene therapies, are in early stages.
5. What are the primary factors influencing future price trends?
Regulatory pressure, competition, diagnostic penetration, and healthcare policy reforms are key determinants.
References
[1] IQVIA. (2023). Pharmaceutical Market Data.
[2] FDA. (2019). Approval letter for Vyndaqel.
[3] EvaluatePharma. (2023). World-Med Market Intelligence.
[4] Centers for Medicare & Medicaid Services. (2022). Coverage and payment policies for rare diseases.
